INTRODUCTION {#s1}
============

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in association with increased platelet destruction and impaired platelet production. It is mediated by IgG antiplatelet autoantibodies in which the targets are platelet membrane glycoproteins (GPs), such as GPIIb/IIIa and GPIb/IX. CD4+CD25+ regulatory T (Treg) cells and CD8+CD28- T lymphocytes have major roles in self-tolerance. To maintain the immune tolerance and to prevent autoimmune disease, CD4+CD25+FoxP3+ Treg cells, CD4+ T cells with high expression of CD25, and transcription factor forkhead box P3 (FoxP3), also referred to as FoxP3 regulatory T cells, play an important role. Treg cells account for approximately 5% of circulating CD4+ T cells. Decreased numbers of Treg cells have been reported in patients with various autoimmune diseases, including ITP, rheumatoid arthritis, and systemic lupus erythematosus \[[@ref1],[@ref2],[@ref3],[@ref4],[@ref5]\].

In the case of Treg deficiency, peripheral tolerance can fail, leading to the development of autoimmunity. The purpose of this study was to evaluate Treg cells in previously untreated newly diagnosed ITP cases.

MATERIALS AND METHODS {#s2}
=====================

Flow Cytometry {#s2a}
--------------

Peripheral blood samples were obtained and studied while still fresh. Flow cytometry was used to count CD4+CD25+ Treg cells and CD8+CD28- suppressive cells. Flow cytometry was performed on a Becton Dickinson FACSCalibur. Data were obtained and analyzed using CellQuest software.

Monoclonal Antibodies {#s2b}
---------------------

Antihuman monoclonal antibodies conjugated with fluorochromes and appropriate isotype controls were used: fluorescein isothiocyanate (FITC) conjugated anti-CD28 (BD Pharmingen Catalog No: 555728), anti-CD4 (Caltag Laboratories Catalog No: MHCD0401), phycoerythrin-cyanine 5 (PC5) conjugated anti-CD8 (eBioscience Catalog No: 15-0088), anti-CD25 (BD Pharmingen Catalog No: 555433), and phycoerythrin (PE) conjugated anti-FoxP3 (eBioscience Catalog No: 12-4776).

Cell Preparation and Surface Staining {#s2c}
-------------------------------------

Human peripheral blood mononuclear cells were isolated using Histopaque (Sigma Catalog No: 1077) gradient centrifugation. Aliquots of 100 µL were transferred to polypropylene test tubes (12x75 mm; BD Bioscience Catalog No: 352052) and 20 µL of conjugated monoclonal antibodies or isotype controls was added to each tube. Flow cytometric analysis was performed by BD FACSCalibur after the appropriate staining protocol.

FoxP3 Staining {#s2d}
--------------

CD4 and CD25 surface staining was carried out. The CD4+CD25 tube was then washed with cold PBS and resuspended, 1 mL of freshly prepared fixation/permeabilization working solution was added, and the tube was incubated at 4 °C for 30-60 min in the dark and washed twice by adding 2 mL of 1X permeabilization buffer. Next, 20 µL of PE conjugated antihuman FoxP3 antibody in 1X permeabilization buffer was added and the tube was incubated at 4 °C for 30 min in the dark. Washing was repeated twice with 2 mL of 1X permeabilization buffer. After resuspension, analysis was performed by flow cytometry.

Analysis {#s2e}
--------

CD8+CD28- cell percentages were evaluated using anti-CD28/anti-CD8 double staining in lymphocyte-gated cells. CD8+CD28- cells, CD8+CD28+ cells, and the ratio of these cells were calculated.

Anti-CD4/anti-FoxP3/anti-CD25 triple staining was uved for CD4+CD25+ Treg cell counts. CD4+CD25high lymphocytes were gated and then CD4+CD25highFoxP3+ cells were calculated in CD4/FoxP3 histograms.

Statistical Analysis {#s2f}
--------------------

Statistical analysis was performed using SPSS. The Mann-Whitney U test was used to investigate immunological parameters of ITP patients and for comparisons with data of healthy subjects.

RESULTS {#s3}
=======

We enrolled 22 previously untreated patients newly diagnosed with ITP (19 males, 3 females) and 16 age-matched controls (13 males, 3 females). All of the patients were admitted to our outpatient clinic. Thrombocytopenia was newly detected and they had received no previous treatment. The patients were investigated for possible causes of thrombocytopenia. Viral serology and other underlying autoimmune diseases were screened. Demographic findings are illustrated in [Table 1](#t1){ref-type="table"}. We performed bone marrow aspiration and biopsy in the relatively elderly patients (patients numbers 5, 9, and 17). No pathological findings such as dysplasia were detected. Findings were consistent with ITP, including normal or increased megakaryocytes.

CD4+CD25+ Treg cells and CD4+CD25highFoxP3+ cells were calculated in lymphocytes. CD4+CD25+ Treg cells were 9.69±3.70% and 12.99±5.58% in patients with ITP and controls, respectively. CD4+CD25highFoxP3+ cells were 27.72±19.74% and 27.55±23.98% in ITP patients and controls, respectively. Both of these cell counts were not statistically different between groups.

We also detected no statistically significant difference in CD8+CD28- suppressor cells between ITP patients and controls (12.50±9.40% and 11.77±4.64%, respectively).

DISCUSSION {#s4}
==========

Treg cells suppress effector T cell activation, which leads to induction of immune tolerance \[[@ref6]\]. For this reason it is assumed that failure of the regulatory T cell system may induce autoimmunity \[[@ref7],[@ref8],[@ref9]\].

There are increasing numbers of studies demonstrating that decreased frequency of Treg cells has a role in ITP. Liu et al. reported that the percentage of Treg cells was significantly decreased in ITP patients with active disease in which no remission was achieved \[[@ref10]\]. Sakakura et al. reported variations in Treg amounts according to platelet counts. In patients with low platelet counts there was no reduction in the percentage of Treg cells when compared to those with platelet counts over 100,000/µL \[[@ref11]\]. In the study by Yu et al., defective circulating CD25 Treg cells were detected in patients with chronic ITP \[[@ref12]\].

However, there are also studies that failed to detect any differences in Treg frequencies of patients with ITP compared to healthy controls \[[@ref13],[@ref14]\].

Similar to our results, Mazzucco et al. detected no significant difference between Treg cell and platelet counts in patients with ITP and the control group \[[@ref15]\].

In our study we investigated previously untreated newly diagnosed ITP patients. We detected no significant difference in Treg cell frequencies in ITP patients and controls. We think that further studies are needed to explore the putative roles of these regulatory cells, especially in terms of long-term follow-ups and response to treatments.
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